| Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer JS Duncan, MC Whittle, K Nakamura, AN Abell, AA Midland, ... Cell 149 (2), 307-321, 2012 | 834 | 2012 |
| Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations CL Liquori, MJ Berg, AM Siegel, E Huang, JS Zawistowski, D Verlaan, ... The American Journal of Human Genetics 73 (6), 1459-1464, 2003 | 372 | 2003 |
| Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains TJ Stuhlmiller, SM Miller, JS Zawistowski, K Nakamura, AS Beltran, ... Cell reports 11 (3), 390-404, 2015 | 335 | 2015 |
| CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis JS Zawistowski, L Stalheim, MT Uhlik, AN Abell, BB Ancrile, GL Johnson, ... Human molecular genetics 14 (17), 2521-2531, 2005 | 289 | 2005 |
| KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis JS Zawistowski, IG Serebriiskii, MF Lee, EA Golemis, DA Marchuk Human molecular genetics 11 (4), 389-396, 2002 | 220 | 2002 |
| Vascular morphogenesis: tales of two syndromes DA Marchuk, S Srinivasan, TL Squire, JS Zawistowski Human molecular genetics 12 (suppl_1), R97-R112, 2003 | 191 | 2003 |
| Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex JS Zawistowski, SM Bevill, DR Goulet, TJ Stuhlmiller, AS Beltran, ... Cancer discovery 7 (3), 302-321, 2017 | 151 | 2017 |
| Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF–MEK–ERK pathway in cancer GL Johnson, TJ Stuhlmiller, SP Angus, JS Zawistowski, LM Graves Clinical Cancer Research 20 (10), 2516-2522, 2014 | 140 | 2014 |
| Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations NW Plummer, CJ Gallione, S Srinivasan, JS Zawistowski, DN Louis, ... The American journal of pathology 165 (5), 1509-1518, 2004 | 130 | 2004 |
| Genetics of cerebral cavernous malformations NW Plummer, JS Zawistowski, DA Marchuk Current neurology and neuroscience reports 5 (5), 391-396, 2005 | 85 | 2005 |
| Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations NW Plummer, TL Squire, S Srinivasan, E Huang, JS Zawistowski, ... Mammalian genome 17, 119-128, 2006 | 74 | 2006 |
| SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling NV Jordan, A Prat, AN Abell, JS Zawistowski, N Sciaky, OA Karginova, ... Molecular and cellular biology, 2013 | 69 | 2013 |
| MAP3K4 controls the chromatin modifier HDAC6 during trophoblast stem cell epithelial-to-mesenchymal transition RJ Mobley, D Raghu, LD Duke, K Abell-Hart, JS Zawistowski, K Lutz, ... Cell reports 18 (10), 2387-2400, 2017 | 62 | 2017 |
| A RhoC biosensor reveals differences in the activation kinetics of RhoA and RhoC in migrating cells JS Zawistowski, M Sabouri-Ghomi, G Danuser, KM Hahn, L Hodgson PLoS One 8 (11), e79877, 2013 | 55 | 2013 |
| GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer SM Bevill, JF Olivares-Quintero, N Sciaky, BT Golitz, D Singh, AS Beltran, ... Molecular Cancer Research 17 (7), 1503-1518, 2019 | 48 | 2019 |
| Kinome and transcriptome profiling reveal broad and distinct activities of erlotinib, sunitinib, and sorafenib in the mouse heart and suggest cardiotoxicity from combined … TJ Stuhlmiller, JS Zawistowski, X Chen, N Sciaky, SP Angus, ST Hicks, ... Journal of the American Heart Association 6 (10), e006635, 2017 | 38 | 2017 |
| Defining the expressed breast cancer kinome AA Midland, MC Whittle, JS Duncan, AN Abell, K Nakamura, ... Cell research 22 (4), 620-623, 2012 | 32 | 2012 |
| Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer KAL Collins, TJ Stuhlmiller, JS Zawistowski, MP East, TT Pham, CR Hall, ... Oncotarget 9 (21), 15480, 2018 | 29 | 2018 |
| Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov. 2017; 7: 302–321. doi: 10.1158/2159-8290 JS Zawistowski, SM Bevill, DR Goulet, TJ Stuhlmiller, AS Beltran, ... CD-16-0653.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 27 | |
| Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2 Synodos for NF2 Consortium, R Allaway, SP Angus, RL Beauchamp, ... PLoS One 13 (6), e0197350, 2018 | 25 | 2018 |
